Tirzepatide (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Once weekly sub-Q on the ladder above. The five day half-life brings any new dose to steady state in about 4 weeks, and pharmacokinetics are linear across 0.25 to 15 mg with no absorption or metabolic break in the curve, so each step should be held at least 4 weeks before the next one. The ladder runs 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg and steps are not skipped. Splitting the weekly dose across 2 to 3 injections is rarely needed, since a five day half-life gives a smoother curve than retatrutide's six day one, but it is useful for severe GI sensitivity because peak concentration rather than weekly total drives GI symptoms. Stop short logic governs the destination: 5 mg retains about 72% of the 15 mg effect, 10 mg retains about 93%, and the 10 to 15 mg step adds only 1.4 percentage points, so for most users the effective dose lives in the 5 to 10 mg band. At this concentration a 10 mg week is a full U-100 syringe and one whole vial, while 12.5 mg and 15 mg exceed one syringe and are given as two injections at separate sites. Sites are rotated systematically across abdomen, thighs, and upper arms to avoid lipohypertrophy.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 4 at 2.5 mg: the floor is already an active dose. Barrea 2026 dose isolated it in obesity without diabetes and measured 4.7% body weight loss, 25% lower fasting insulin, and a 30% drop in insulin resistance score over 4 weeks, with tolerability indistinguishable from 5 mg.
• Weeks 5 onward: steady state arrives about 4 weeks after any new dose, so GI tolerability at a given rung is only fully readable near the end of its hold. GI symptoms are worst during the climb and settle with time at a fixed dose.
• Week 72 anchors from SURMOUNT-1: 15.0% mean weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, against 3.1% on placebo.
• Continuation phase: in the 52 week withdrawal study 89.5% of continuators held at least 80% of their loss, while switching to placebo produced 14% regain. Continuation matters more than which rung was reached, within reason.
• Step down, if used: reducing 15 to 10 to 7.5 to 5 mg in 8 to 12 week increments is clinically reasonable but not yet directly trial validated, with SURMOUNT-MAINTAIN ongoing. Regain after a reduction reportedly arrives faster than washout pharmacokinetics alone would predict, so quick drift is a signal to slow the step down cadence.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.
5. Ladder conversions at 10 mg/mL: 2.5 mg = 25 units; 5 mg = 50 units; 7.5 mg = 75 units; 10 mg = 100 units, which is one whole vial and a full U-100 syringe; 12.5 mg = 125 units and 15 mg = 150 units, each of which exceeds one syringe and splits into two injections.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze thaw cycles.

• Allow vials to reach room temperature before opening, which reduces condensation uptake.
• Keep reconstituted vials out of the refrigerator door, where temperature swings are largest, and label each one with date and concentration so draw volumes are never guessed. At 1.0 mL per vial a 10 mg vial holds exactly two 5 mg doses or one 10 mg dose, so nothing is stranded if draws are planned before the first one.

Supplies Needed

Planning math is based on a 16 week titration from 2.5 mg up to 5 mg weekly, then 5 mg weekly maintenance, which is the modal real world dose.

Peptide Vials (Tirzepatide, 10 mg vial):

• The 16 week titration totals about 52 mg, which is about 5 vials at 10 mg each. Ongoing maintenance at 5 mg weekly runs 20 mg per month, about 2 vials; 10 mg weekly runs 40 mg per month, about 4 vials; a 2.5 mg metabolic dose runs 10 mg per month, about 1 vial.

Insulin Syringes (U-100):

• Per week: 1 U-100 syringe at doses through 10 mg, and 2 at 12.5 or 15 mg because the volume exceeds one syringe.
• Full cycle: 16 syringes across the 16 week titration and 52 across a year of weekly maintenance at 5 mg; double either figure at the top two rungs or when a weekly dose is split for GI tolerance.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle covers 10 vials: 1 bottle for the 16 week titration and about 3 bottles for a year of 5 mg weekly maintenance, more at higher doses.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the skin.
• Full cycle: about 32 swabs over the 16 week titration and about 104 for a year of weekly maintenance, which one 100 count box covers.

Important Notes

Practical considerations for consistency and safety.

• Stop short is the load bearing dose decision. 5 mg gives about 72% of maximum effect and 10 mg about 93%, while the 10 to 15 mg step adds only 1.4 percentage points and GI burden keeps scaling with dose. Real world prescribing has already converged there: across 5 cohorts totaling more than 40,000 users, 56 to 74% of persistent users sit below 10 mg by their sixth prescription and modal maintenance is 5 mg, with 6 month weight loss of 11 to 13% in users without diabetes. Body weight is not a clinically relevant pharmacokinetic covariate for tirzepatide, unlike semaglutide, so the same ladder applies regardless of starting weight.
• 2.5 mg is no longer only a titration step. Barrea 2026 (n=70, dose isolated over 4 weeks) measured 4.7% body weight loss, 25% lower fasting insulin, and a 30% drop in insulin resistance score, with tolerability indistinguishable from 5 mg. That is the first direct measurement of 2.5 mg as a flat dose and makes it a reasonable metabolic dose for insulin resistance, PCOS, or modest weight loss goals.
• Evidence grades by band: 0.5 to 2 mg is microdose territory, mechanism consistent with a directly measured 1 mg HbA1c effect from the Phase 2 dose range trial; 2.5 mg is directly measured; 5 mg is directly measured at about 15.0% over 72 weeks; 7.5 to 10 mg is the value tier with 10 mg directly measured; 12.5 to 15 mg is directly measured at about 20.9%. Above 15 mg has zero prospective data. Every trial capped there, linear pharmacokinetics extrapolate but carry no efficacy argument against a flattening curve, and compounded 30 or 60 mg vials are unit economics packaging for dosing below 15 mg.
• Heart rate rises modestly and with dose: about 0.6 bpm at 5 mg, 2.3 bpm at 10 mg, and 2.6 bpm at 15 mg over 72 weeks against 0.1 bpm on placebo, smaller than retatrutide's glucagon driven rise but worth watching with tachyarrhythmia or autonomic concerns. The label also carries an oral contraceptive warning: gastric emptying delay is strongest after initiation and after each escalation and can drop oral contraceptive exposure, so a non oral or barrier method covers the titration windows.
• Switching from semaglutide starts at 2.5 to 5 mg regardless of the prior semaglutide dose, since there is no clean milligram for milligram conversion across different receptor systems and some GI adjustment is expected even when semaglutide was tolerated well. Contraindications named in the source material: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, pregnancy or breastfeeding, severe gastroparesis, and severe diabetic retinopathy. This is the evidence led choice for obesity without diabetes where body composition is the priority, for weight loss magnitude, after a semaglutide plateau, and in type 2 diabetes with a body composition concern; it is not the evidence led choice for cardiovascular protection in obesity without diabetes, for MASH histologic resolution, or where an oral option is needed.
• Regulatory Note: tirzepatide is FDA approved, as Mounjaro for type 2 diabetes and as Zepbound for obesity. Research grade compounded vials sold at 10 to 60 mg are containers for dosing below 15 mg, not a license to exceed the trial safety envelope. WADA status is not addressed in the source material.

How This Works

Tirzepatide activates two incretin receptors with deliberately imbalanced potency: the GLP-1 receptor at 0.2x native and the GIP receptor at 1.0x native. That asymmetry is what makes the ladder a receptor mix rather than a strength dial, since lower doses are GIP forward and higher doses bring progressively more GLP-1 appetite pressure. On the GLP-1 side the drug slows gastric emptying, strengthens satiety signaling at brainstem and hypothalamic sites, and improves glucose dependent insulin release; it is the same pathway semaglutide uses, engaged at a fifth of native potency, which is why tirzepatide can produce a less GLP-1 heavy tolerability profile at comparable weight loss. On the GIP side it improves insulin efficiency, meaning less hormone is needed for the same glucose handling, and it engages fat tissue directly through SERCA mediated futile calcium cycling in white adipocytes, a heat producing and energy consuming process. Pure GLP-1 agonists cannot reach that pathway at all because GLP-1 receptors are not expressed in adipose tissue, and this is the structural basis for the 75:25 fat to lean DXA ratio seen in obesity without diabetes. The important caveat is that GIP receptor responsiveness is impaired in type 2 diabetes, the incretin defect, so the fat selective ratio advantage narrows or disappears in head to head diabetes data even though tirzepatide still delivers more absolute fat loss than semaglutide there. That specific limitation is what motivated retatrutide's design: 8.9x native GIP potency to push through impaired receptors, plus a glucagon arm that bypasses the GIP defect entirely through direct liver action. Pharmacokinetics are straightforward by comparison: a five day half-life, steady state in about 4 weeks at any new dose, linear behavior from 0.25 to 15 mg, and 80% bioavailability, with body weight not a clinically relevant covariate. Antibodies against the drug appear in 51 to 64% of users, far above the 1 to 3% seen with semaglutide; clinical impact has been silent so far, but the long horizon immunogenicity question stays open.

Benefits & Side Effects

Observations from the published record.

• Weight loss anchors from SURMOUNT-1 (Jastreboff NEJM 2022), 72 weeks in obesity without diabetes: 3.1% on placebo, 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. Among 15 mg participants, 57% reached 20% or more total loss and 36% reached 25% or more.
• Dose response shape: each added milligram bought about 0.9% across the 5 to 10 mg step but only about 0.28% across the 10 to 15 mg step, a threefold collapse in return per milligram. 5 mg captures roughly 72% of maximum effect and 10 mg roughly 93%.
• Head to head magnitude, SURMOUNT-5 (Aronne NEJM 2024): 20.2% on tirzepatide against 13.7% on semaglutide at maximum tolerated doses over 72 weeks, a 47% magnitude advantage and the largest gap in the class, with 31.6% reaching 25% or more against 16.1%. The open label design probably overstates the size a little, but the direction holds against blinded dose response evidence.
• Body composition is population dependent. The DXA substudy (Look DOM 2025) found a 75:25 fat to lean ratio at therapeutic doses in obesity without diabetes, conserved across sex, age band, and total weight loss tier rather than resting on a fragile subgroup. In type 2 diabetes the head to head clamp study read about 87:13 against 86:14 for semaglutide, so the ratio advantage collapses; absolute fat loss still favors tirzepatide, but the ratio story is specific to users without diabetes.
• Other endpoints: in type 2 diabetes over 40 weeks (Frias NEJM 2021) tirzepatide 15 mg produced about 13% weight loss against about 6% for semaglutide 1 mg, with HbA1c reductions of 2.0 to 2.3%, the largest reported for any incretin. Liver fat and visceral fat fell substantially with muscle quality improvement (Gastaldelli 2022), and SYNERGY-NASH reported 62% MASH inflammation resolution at 15 mg against 10% on placebo. SURPASS-CVOT showed non inferiority against dulaglutide, a different evidentiary standard than semaglutide's placebo beaten SELECT signal.
• Side effects at 15 mg over 72 weeks: nausea 33%, diarrhea 23%, constipation 17%, vomiting 12%, abdominal pain 10%, dyspepsia 9%, all worst during titration and often milder on the lower rungs. Gallbladder risk is elevated about 1 to 2%, a less prominent biliary signal than semaglutide shows in the current comparison set. Antibodies against the drug run 51 to 64% against 1 to 3% for semaglutide, with no clinical signal so far. Some users find it less energy flattening than semaglutide, consistent with the lighter GLP-1 weighting.

Lifestyle Factors

Complementary strategies for best outcomes.

• Protein at 1.0 to 1.2 g per pound of goal weight per day, which is what locks the 75:25 ratio in place; without it lean loss creeps higher even on tirzepatide. Protein first meals matter here, because early satiety from gastric slowing makes the daily target hard to hit once fullness arrives.
• Resistance training 3 to 4 times weekly, the mechanical signal that directs the fat selective advantage. Cardio alone is not sufficient for muscle preservation during an aggressive deficit.
• Hydration, electrolytes, and fiber, since GI effects amplify with dehydration and both constipation and heart rate drift worsen. Magnesium citrate, psyllium, and adequate water address the 17% constipation rate at the top dose; smaller and more frequent meals help through titration; alcohol is limited during the climb, since tolerance drops sharply and it works against the metabolic gains. Sleep of 7 to 9 hours keeps cortisol driven cravings from fighting the appetite effect.
• Baseline labs before starting, repeated at month 3 and month 6: fasting glucose, HbA1c, lipid panel, liver enzymes (ALT and AST), and a kidney panel, with resting heart rate tracked weekly through titration where a small dose dependent rise is expected. Some protocols pair tesamorelin for lean mass preservation during a deficit, since nocturnal growth hormone driven protein synthesis sits well alongside daytime appetite suppression, or MOTS-c or NAD+ for mitochondrial support; neither is required.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen avoiding 2-inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
5. Dispose of needles and syringes in a sharps container immediately after use.

References

Source citations for further reading.

1. Jastreboff AM et al. SURMOUNT-1: tirzepatide for obesity, about 21% at 15 mg over 72 weeks (NEJM, 2022).
2. Aronne LJ et al. SURMOUNT-5: tirzepatide vs semaglutide, 20.2% vs 13.7% (NEJM, 2024).
3. Look et al. DXA body composition substudy: 75:25 fat to lean conserved across subgroups (DOM, 2025).
4. Yu et al. Adipocyte GIP receptor drives fat cell thermogenesis via SERCA futile cycling (Cell Metab, 2024).
5. Willard et al. Tirzepatide receptor pharmacology, imbalanced agonism (JCI Insight, 2020).
6. Barrea L et al. 2.5 mg dose isolated, 4 weeks, n=70: 4.7% weight loss, 25% lower fasting insulin (EXCLI Journal, 2026).